Kristin Nyberg

Kristin Nyberg has a diverse and extensive work experience. Starting in 1994, they worked as a Sales Representative at MSD. Kristin then moved on to roles such as Executive Officer at The Norwegian Confederation of Trade Unions, and Productspecialist at Merck Serono.

In 1999, they joined Roche as a Productmanager, where they successfully launched two monoclonal antibodies in Norway. Kristin also served as a Nordic representative in the MabThera International Business Team at Roche headquarters.

In 2005, they joined Photocure ASA as a Productmanager before transitioning to the role of Business Unit Manager at Abbott in 2006.

Kristin then worked at Biogen from 2007 to 2019, first as a Senior Country Manager and later as a Country Director. In this role, they were responsible for managing the Norwegian affiliate, leading a team, ensuring market access for products, and complying with all local regulations.

In 2019, they worked as a Governmental Affairs/Public Affairs Business Consultant at Nyberg Consulting, and as a Board Member at Observe Medical.

Currently, they serve as the Head of Nordic at Photocure ASA.

Kristin Nyberg's education history began in 1982 when they attended Lørenskog Videregående Skole, a senior high school in Norway, where they focused on the field of science and mathematics. In 1986, they enrolled at Linköping University, studying at the Department of Physics until 1987. The following year, from 1988 to 1989, they continued their education at Linköping University, this time focusing on the Department of Biology.

In 1990, Kristin Nyberg started their studies at the University of Oslo (UiO) in Norway, pursuing a Master of Science (M.Sc.) degree in the field of Cell/Cellular and Molecular Biology. Kristin successfully completed their degree in 1993.

Afterward, Kristin Nyberg undertook postgraduate medical education at The Norwegian Medical Association. In 2001, they took the "Cancer mammae, diagnosis, treatment and adjuvant therapy" course (O-3740), and in the same year, they also completed the "Haematological diseases exclusive of malignant lymphomas. Diagnosis and treatment" course (O-3814). However, the exact start and end years for these courses are not provided.

Also, the information states that Kristin Nyberg completed a "Malignant Lymphomas" course (O-4075) at The Norwegian Medical Association, but the start and end years for this course are not specified.

Finally, in 1994, Kristin Nyberg obtained certification from The Norwegian Pharmaceutical Association.

Overall, Kristin Nyberg has a diverse education history, with a background in science, biology, medicine, and molecular biology.